MRD‑AI Integration

Personalis brings its flagship NeXT Personal test, an MRD‑based assay that detects circulating tumor DNA to monitor cancer recurrence. The test already has Medicare coverage in three indications and sits within a rapidly expanding market that the two companies value at $20 billion. By integrating Personalis’s ultrasensitive MRD technology with Tempus’s multimodal data platform and AI capabilities, the combined entity aims to expand longitudinal monitoring, accelerate biomarker discovery, and enhance personalized cancer care.